Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Translational Quantitative Systems Pharmacology in Drug Development: from Current Landscape to Good Practices.

Bai JPF, Earp JC, Pillai VC.

AAPS J. 2019 Jun 3;21(4):72. doi: 10.1208/s12248-019-0339-5.

PMID:
31161268
2.

The Utility of a Population Approach in Drug-Drug Interaction Assessments: A Simulation Evaluation.

Wang DD, Yu Y, Kassir N, Zhu M, Hanley WD, Earp JC, Chow AT, Gupta M, Hu C.

J Clin Pharmacol. 2017 Oct;57(10):1268-1278. doi: 10.1002/jcph.921. Epub 2017 May 17.

PMID:
28513856
3.

Esomeprazole FDA Approval in Children With GERD: Exposure-Matching and Exposure-Response.

Earp JC, Mehrotra N, Peters KE, Fiorentino RP, Griebel D, Lee SC, Mulberg A, Röhss K, Sandström M, Taylor A, Tornøe CW, Wynn EL, Van der Walt JS, Garnett C.

J Pediatr Gastroenterol Nutr. 2017 Sep;65(3):272-277. doi: 10.1097/MPG.0000000000001467.

PMID:
27875488
4.

Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling.

Mehrotra N, Bhattaram A, Earp JC, Florian J, Krudys K, Lee JE, Lee JY, Liu J, Mulugeta Y, Yu J, Zhao P, Sinha V.

Drug Metab Dispos. 2016 Jul;44(7):924-33. doi: 10.1124/dmd.116.069559. Epub 2016 Apr 14. Review.

PMID:
27079249
5.

Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group.

Bonate PL, Ahamadi M, Budha N, de la Peña A, Earp JC, Hong Y, Karlsson MO, Ravva P, Ruiz-Garcia A, Struemper H, Wade JR.

J Pharmacokinet Pharmacodyn. 2016 Apr;43(2):123-35. doi: 10.1007/s10928-016-9464-2. Epub 2016 Feb 2. Review.

PMID:
26837775
6.

Modeling effects of dexamethasone on disease progression of bone mineral density in collagen-induced arthritic rats.

Lon HK, DuBois DC, Earp JC, Almon RR, Jusko WJ.

Pharmacol Res Perspect. 2015 Oct;3(5):e00169. doi: 10.1002/prp2.169. Epub 2015 Aug 3.

7.

Utility of population pharmacokinetic modeling in the assessment of therapeutic protein-drug interactions.

Chow AT, Earp JC, Gupta M, Hanley W, Hu C, Wang DD, Zajic S, Zhu M; Population PK TPDI Working Group.

J Clin Pharmacol. 2014 May;54(5):593-601. doi: 10.1002/jcph.240. Epub 2013 Dec 6.

PMID:
24272952
8.

Therapeutic protein drug-drug interactions: navigating the knowledge gaps-highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA workshop.

Kenny JR, Liu MM, Chow AT, Earp JC, Evers R, Slatter JG, Wang DD, Zhang L, Zhou H.

AAPS J. 2013 Oct;15(4):933-40. doi: 10.1208/s12248-013-9495-1. Epub 2013 Jun 21.

9.

Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008.

Lee JY, Garnett CE, Gobburu JV, Bhattaram VA, Brar S, Earp JC, Jadhav PR, Krudys K, Lesko LJ, Li F, Liu J, Madabushi R, Marathe A, Mehrotra N, Tornoe C, Wang Y, Zhu H.

Clin Pharmacokinet. 2011 Oct;50(10):627-35. doi: 10.2165/11593210-000000000-00000.

PMID:
21895036
10.

Down-regulation of heat shock protein 70 improves arsenic trioxide and 17-DMAG effects on constitutive signal transducer and activator of transcription 3 activity.

Ghoshal S, Rao I, Earp JC, Jusko WJ, Wetzler M.

Cancer Chemother Pharmacol. 2010 Sep;66(4):681-9. doi: 10.1007/s00280-009-1210-7. Epub 2009 Dec 25.

11.

Quantitative dynamic models of arthritis progression in the rat.

Earp JC, Dubois DC, Almon RR, Jusko WJ.

Pharm Res. 2009 Jan;26(1):196-203. doi: 10.1007/s11095-008-9711-3. Epub 2008 Aug 30.

12.

Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies.

Drake AS, Brady MT, Wang XH, Sait SJ, Earp JC, Ghoshal Gupta S, Ferrone S, Wang ES, Wetzler M.

Cancer Immunol Immunother. 2009 Mar;58(3):415-27. doi: 10.1007/s00262-008-0567-5. Epub 2008 Aug 2.

13.

Pharmacokinetics of dexamethasone in a rat model of rheumatoid arthritis.

Earp JC, Pyszczynski NA, Molano DS, Jusko WJ.

Biopharm Drug Dispos. 2008 Sep;29(6):366-72. doi: 10.1002/bdd.626.

14.

Modeling corticosteroid effects in a rat model of rheumatoid arthritis I: mechanistic disease progression model for the time course of collagen-induced arthritis in Lewis rats.

Earp JC, Dubois DC, Molano DS, Pyszczynski NA, Keller CE, Almon RR, Jusko WJ.

J Pharmacol Exp Ther. 2008 Aug;326(2):532-45. doi: 10.1124/jpet.108.137372. Epub 2008 Apr 30.

15.

Modeling corticosteroid effects in a rat model of rheumatoid arthritis II: mechanistic pharmacodynamic model for dexamethasone effects in Lewis rats with collagen-induced arthritis.

Earp JC, Dubois DC, Molano DS, Pyszczynski NA, Almon RR, Jusko WJ.

J Pharmacol Exp Ther. 2008 Aug;326(2):546-54. doi: 10.1124/jpet.108.137414. Epub 2008 Apr 30.

Supplemental Content

Support Center